GE Healthcare and SonoMotion sign a second co-development agreement and expand their strategic relationship with an updated OEM agreement.
SonoMotion receives Health Canada ITA approval to initiate its Break Wave™ First-In-Human clinical trial in Canada.
SonoMotion receives FDA IDE approval to initiate its Break Wave™ First-In-Human clinical trial in the United States.
GE Healthcare and SonoMotion establish a strategic partnership and sign a definitive OEM agreement and co-development agreement.
SonoMotion receives a $1.0M SBIR Commercial Readiness Program grant from the NIH for the development of Stone Clear™.